We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Futura Medical

FY21 is set to be a year of execution

Update | 14 April 2021

HUTCHMED

Baring Private Equity Asia invests $100m

Lighthouse | 08 April 2021

Nexstim

Rights issue 178% oversubscribed

Lighthouse | 08 April 2021

HUTCHMED

Breaking new ground in China and globally

Outlook | 30 March 2021

Futura Medical

EU Notified Body recommends MED3000 approval

Lighthouse | 19 March 2021

Nexstim

Subscription rights issue of €6.6m at €0.03 per share

Lighthouse | 08 March 2021

Hutchison China MediTech

Transitioning to a global oncology player

Lighthouse | 05 March 2021

Futura Medical

Commercialisation deal for China and SE Asia

Update | 04 March 2021

Nexstim

A positive start to the 2020-24 strategy

Update | 04 March 2021

Nexstim

Promising results for severe depression pilot study

Lighthouse | 03 March 2021
1 2 3 4 5 6 7 8 9 10 >
241 results found.